knowledge -WSS

knowledge

author：hotspot 2025-10-02 19:15:30 - browse：45278

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： New Ultima Genomics DNA sequencer can read genome for $100

WSS

Vertigo drug brings hope for rare neuron disorder, Niemann

In diabetes hearing, Sanders takes on a new foe: food makers

Biden administration opens offers in Medicare drug price negotiations

Do digital therapeutics have a future in medicine?

Covid misinformation case heads to Supreme Court

FDA needs staff influx to meet gene therapy needs, Marks says

focus

knowledge

focus

As demand for Covid shots wanes, Moderna seeks its next success

Quicker fix for pulse oximeters urged during FDA public meeting

Jerome Adams on the need for new antivirals for Covid

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Congressmen charge Covid hearing ‘could have been an email’

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Apple Vision Pro: A first look at health apps on the new VR headset

Tori Bowie and the unacceptable rates of Black maternal death

Woodcock on FDA’s accelerated approval and her next chapter

entertainment

New Ultima Genomics DNA sequencer can read genome for $100

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Woodcock on FDA’s accelerated approval and her next chapter

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

CMS should re

Do digital therapeutics have a future in medicine?

hotspot

entertainment

Wikipedia

hotspot